Acamprosate: Safety and tolerability in the treatment of alcohol dependence

Journal of Addiction Medicine

Volumn 2, Issue 1, 2008, Pages 40-50

  Rosenthal, Richard N ^a   Gage, Allyson ^b   Perhach, James L ^b   Goodman, Anita M ^c  

^a Surgeons and St Luke's Roosevelt Hospital Center ^*  (United States)

^b FOREST RESEARCH INSTITUTE   (United States)

^c Lipha Pharmaceuticals Inc   (United States)

Author keywords

Acamprosate; Adverse events; Alcohol dependence; Clinical trials; Safety

Indexed keywords

EID: 70349227144     PISSN: 19320620     EISSN: 19353227     Source Type: Journal    
DOI: 10.1097/ADM.0b013e31816319fd     Document Type: Article

References (47)

1. Mason BJ. Acamprosate in the treatment of alcohol dependence. Expert Opin Pharmacother. 2005;6:2103-2115.
2. Mason BJ, Goodman AM, Chabac S, et al. Effect of oral acamprosate on abstinence in patients with alcohol dependence in a double-blind, placebo-controlled trial: The role of patient motivation. J Psychiatr Res. 2006;40:383-393.
3. Anton RF, O'Malley SS, Ciraulo DA, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: The COMBINE study: A randomized controlled trial. JAMA. 2006;295:2003-2017.
4. Naassila M, Hammoumi S, Legrand E, et al. Mechanism of action of acamprosate. Part, I Characterization of spermidine-sensitive acamprosate binding site in rat brain. Alcohol Clin Exp Res. 1998;22:802-809.
5. al Qatari M, Bouchenafa O, Littleton J. Mechanism of action of acamprosate. Part II. Ethanol dependence modifies effects of acamprosate on NMDA receptor binding in membranes from rat cerebral cortex. Alcohol Clin Exp Res. 1998;22:810-814.
6. Harris BR, Prendergast MA, Gibson DA, et al. Acamprosate inhibits the binding and neurotoxic effects of trans-ACPD, suggesting a novel site of action at metabotropic glutamate receptors. Alcohol Clin Exp Res. 2002;26:1779-1793.
7. Harris BR, Gibson DA, Prendergast MA, et al. The neurotoxicity induced by ethanol withdrawal in mature organotypic hippocampal slices might involve cross-talk between metabotropic glutamate type 5 receptors and N-methyl-D-aspartate receptors. Alcohol Clin Exp Res. 2003;27:1724-1735.
8. Littleton JM. Acamprosate in alcohol dependence: Implications of a unique mechanism of action. J Addict Med. 2007;1:115-125.
9. Tambour S, Quertemont E. Preclinical and clinical pharmacology of alcohol dependence. Fundam Clin Pharmacol. 2007;21:9-28.
10. Mihic SJ, Harris RA. GABA and the GABAA receptor. Alcohol Health Res World. 1997;21:127-131.
11. Gonzales RA, Jaworski JN. Alcohol and glutamate. Alcohol Health Res World. 1997;21:120-127.
12. Davies M. The role of GABAA receptors in mediating the effects of alcohol in the central nervous system. J Psychiatry Neurosci. 2003;28: 263-274.
13. Krystal JH, Petrakis IL, Mason G, et al. N-methyl-D-aspartate glutamate receptors and alcoholism: reward, dependence, treatment, and vulnerability. Pharmacol Ther. 2003;99:79-94.
14. Samson HH, Harris RA. Neurobiology of alcohol abuse. Trends Phar- macolSci. 1992;13:206-211.
15. Criswell HE, Simson PE, Knapp DJ, et al. Effect of zolpidem on gamma-aminobutyric acid (GABA)-induced inhibition predicts the interaction of ethanol with GABA on individual neurons in several rat brain regions. J Pharmacol Exp Ther. 1995;273:526-536.
16. Devaud LL, Alele P. Differential effects of chronic ethanol administration and withdrawal on gamma-aminobutyric acid type A and NMDA receptor subunit proteins in male and female rat brain. Alcohol Clin Exp Res. 2004;28:957-965.
17. Swift RM. Drug therapy for alcohol dependence. N Engl J Med. 1999;340:1482-1490.
18. Littleton J, Zieglgansberger W. Pharmacological mechanisms of naltrex- one and acamprosate in the prevention of relapse in alcohol dependence. Am J Addict. 2003;12(Suppl 1):S3-S11.
19. Girault J, Gobin P, Fourtillan JB. Determination of calcium acetylho-motaurinate in human plasma and urine by combined gas chromatogra- phy-negative-ion chemical ionization mass spectrometry. J Chromatogr. 1990;530:295-305. (Pubitemid 20276118)
20. Chabenat C, Ladure P, Moore N, et al. Application of an analytical method to calcium acetylhomotaurinate determination in urine. Arzne-imittelforschung. 1989;39:1413-1414.
21. Saivin S, Hulot T, Chabac S, et al. Clinical pharmacokinetics of acamprosate. Clin. Pharmacokinet. 1998;35:331-345.
22. Barrias JA, Chabac S, Ferreira L, et al. Acamprosate: Multicenter Portuguese efficacy and tolerance evaluation study. Psiquiatria Clinica. 1997;18:149-160.
23. Chick J, Howlett H, Morgan MY, et al. United Kingdom Multicentre Acamprosate Study (UKMAS): A 6-month prospective study of acam- prosate versus placebo in preventing relapse after withdrawal from alcohol. Alcohol Alcohol. 2000;35:176-187.
24. Geerlings PJ, Ansoms C, van den Brink W. Acamprosate and prevention of relapse in alcoholics. Eur Addict Res. 1997;3:129-137.
25. Gual A, Lehert P. Acamprosate during and after acute alcohol withdrawal: A double-blind placebo-controlled study in Spain. Alcohol Alcohol. 2001;36:413-418.
26. Ladewig D, Knecht T, Leher P, et al. [Acamprosate-a stabilizing factor in long-term withdrawal of alcoholic patients.] Ther Umsch. 1993;50:182-188.
27. Pelc I, Verbanck P, Le Bon O, et al. Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients. A 90-day placebo- controlled dose-finding study. Br J Psychiatry. 1997;171:73-77.
28. Poldrugo F. Acamprosate treatment in a long-term community-based alcohol rehabilitation programme. Addiction. 1997;92:1537-1546.
29. Tempesta E, Janiri L, Bignamini A, et al. Acamprosate and relapse prevention in the treatment of alcohol dependence: A placebo-controlled study. Alcohol Alcohol. 2000;35:202-209.
30. Paille FM, Guelfi JD, Perkins AC, et al. Double-blind randomized multicentre trial of acamprosate in maintaining abstinence from alcohol. Alcohol Alcohol. 1995;30:239-247.
31. Sass H, Soyka M, Mann K, et al. Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence. Arch Gen Psychiatry. 1996;53:673-680.
32. Whitworth AB, Fischer F, Lesch OM, et al. Comparison of acamprosate and placebo in long-term treatment of alcohol dependence. Lancet. 1996;347:1438-1442.
33. Besson J, Aeby F, Kasas A, et al. Combined efficacy of acamprosate and disulfiram in the treatment of alcoholism: a controlled study. Alcohol Clin Exp Res. 1998;22.
34. Spilker B. Multinational Drug Companies: Issues in Drug Discovery and Development. New York, NY: Raven Press; 1989:361-397.
35. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 3rd ed. Washington, DC: American Psychiatric Association; 1980.
36. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 3rd ed revised. Washington, DC: American Psychiatric Association; 1987.
37. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed revised. Washington, DC: American Psychiatric Association; 2004.
38. Pages KP, Russo JE, Roy-Byrne PP, etal. Determinants ofsuicidal ideation: the role ofsubstance use disorders. J Clin Psychiatry. 1997;58:510-517.
39. Durbin P, Hulot T, Chabac S. Pharmacodynamics and pharmacokinetics of acamprosate: An overview. In: Soyka M, ed. Acamprosate in Relapse Prevention of Alcoholism. Proceedings of the 1st Campral Symposium. Stuttgart, Germany: Springer; 1995:47-64.
40. Wernicke JF, Faries D, Milton D, et al. Detecting treatment emergent adverse events in clinical trials: a comparison of spontaneously reported and solicited collection methods. Drug Saf. 2005;28:1057-1063.
41. Lhuintre JP, Moore N, Tran G, et al. Acamprosate appears to decrease alcohol intake in weaned alcoholics. Alcohol Alcohol. 1990;25:613-622.
42. Lhuintre JP, Daoust M, Moore ND, et al. Ability of calcium bis acetyl homotaurine, a GABA agonist, to prevent relapse in weaned alcoholics. Lancet. 1985;1:1014-1016.
43. Baltieri DA, De Andrade AG. Efficacy of acamprosate in the treatment of alcohol-dependent outpatients. Revista Brasileira de Psiquiatria. 2003;25:156-159.
44. Baltieri DA, De Andrade AG. Acamprosate in alcohol dependence: A randomized controlled efficacy study in a standard clinical setting. J Stud Alcohol. 2004;65:136-139.
45. Namkoong K, Lee B-O, Lee P-G, et al. Acamprosate in Korean alcohol-dependent patients: A multi-centre, randomized, double-blind, placebo-controlled study. Alcohol Alcohol. 2003;38:135-141.
46. Rousseaux JP, Hers D, Ferauge M. Does acamprosate diminish the appetite for alcohol in weaned alcoholics? J Pharm Belg. 1996;51:65-68.
47. Kiefer F, Jahn H, Tarnaske T, et al. Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. Arch Gen Psychiatry. 2003; 60:92-99.